Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene
Phase 1
Recruiting
- Conditions
- Retinitis Pigmentosa
- Interventions
- Biological: AAV2/5-hPDE6B
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- eyeDNA Therapeutics
- Target Recruit Count
- 23
- Registration Number
- NCT03328130
- Locations
- 🇫🇷
Clinique Ophtalmologique, CHU de Nantes, Nantes, France
© Copyright 2025. All Rights Reserved by MedPath